Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Crazy About Novavax, Inc. (NVAX): Obagi Medical Products, Inc. (OMPI), Vical Incorporated (VICL)

Page 1 of 2

Novavax, Inc. (NASDAQ:NVAX) was in 5 hedge funds’ portfolio at the end of December. NVAX investors should pay attention to an increase in hedge fund interest of late. There were 4 hedge funds in our database with NVAX positions at the end of the previous quarter.

Peter Kolchinsky

In today’s marketplace, there are a multitude of indicators market participants can use to analyze the equity markets. A duo of the most innovative are hedge fund and insider trading sentiment. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the elite money managers can beat the market by a superb margin (see just how much).

Just as integral, bullish insider trading activity is another way to break down the marketplace. As the old adage goes: there are a variety of incentives for an executive to cut shares of his or her company, but only one, very simple reason why they would behave bullishly. Various empirical studies have demonstrated the impressive potential of this strategy if piggybackers understand what to do (learn more here).

Keeping this in mind, it’s important to take a glance at the latest action surrounding Novavax, Inc. (NASDAQ:NVAX).

How are hedge funds trading Novavax, Inc. (NASDAQ:NVAX)?

Heading into 2013, a total of 5 of the hedge funds we track held long positions in this stock, a change of 25% from one quarter earlier. With hedge funds’ positions undergoing their usual ebb and flow, there exists a select group of key hedge fund managers who were boosting their holdings substantially.

Of the funds we track, Peter Kolchinsky’s RA Capital Management had the largest position in Novavax, Inc. (NASDAQ:NVAX), worth close to $27.2 million, comprising 9.6% of its total 13F portfolio. On RA Capital Management’s heels is Jay Venkatesen of Ayer Capital Management, with a $5.2 million position; the fund has 2.7% of its 13F portfolio invested in the stock. Some other hedgies that are bullish include D. E. Shaw’s D E Shaw, and Glenn Russell Dubin’s Highbridge Capital Management.

Now, key hedge funds have jumped into Novavax, Inc. (NASDAQ:NVAX) headfirst. Ayer Capital Management, managed by Jay Venkatesen, created the largest position in Novavax, Inc. (NASDAQ:NVAX). Ayer Capital Management had 5.2 million invested in the company at the end of the quarter. Peter Kolchinsky’s RA Capital Management also made a $0.2 million investment in the stock during the quarter. The only other fund with a new position in the stock is Glenn Russell Dubin’s Highbridge Capital Management.

What do corporate executives and insiders think about Novavax, Inc. (NASDAQ:NVAX)?

Insider trading activity, especially when it’s bullish, is at its handiest when the company we’re looking at has experienced transactions within the past six months. Over the last six-month time period, Novavax, Inc. (NASDAQ:NVAX) has seen 1 unique insiders buying, and zero insider sales (see the details of insider trades here).

Let’s also review hedge fund and insider activity in other stocks similar to Novavax, Inc. (NASDAQ:NVAX). These stocks are Obagi Medical Products, Inc. (NASDAQ:OMPI), Vical Incorporated (NASDAQ:VICL), Osiris Therapeutics, Inc. (NASDAQ:OSIR), 3SBio Inc. (ADR) (NASDAQ:SSRX), and XenoPort, Inc. (NASDAQ:XNPT). All of these stocks are in the biotechnology industry and their market caps are closest to NVAX’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!